Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Evusheld

- PMLiVE

AstraZeneca steps up cancer immunotherapy research

MedImmune unit will study anti-PD1 drug in combination with Advaxis’ cervical cancer vaccine

- PMLiVE

AZ unveils plans for new Cambridge HQ

Construction of its Cambridge Biomedical Campus will start early next year

National Institute for Health and Care Excellence NICE logo

NICE confirms wider statin use

Reduces threshold for risk of heart disease

Biogen Idec building

NICE green light for Biogen’s oral MS drug

Overturns previous negative guidance for Tecfidera

- PMLiVE

NICE backs Lundbeck’s alcohol dependence drug Selincro

Alcoholics in England to have access to once-daily drug

- PMLiVE

AZ sues to block generic saxagliptin from Mylan

Attempt to protect diabetes treatments Onglyza and Kombiglyze XR

- PMLiVE

AZ needs more data on olaparib, says FDA panel

Agency advisers demands more safety information on ovarian cancer drug

- PMLiVE

NICE backs Janssen’s once-daily diabetes drug

Invokana is the tenth treatment recommended in England and Wales to lower blood sugar levels

AZ expands its mHealth services with new COPD initiative

Partners with Exco InTouch to launch Me&MyCOPD programme

National Institute for Health and Care Excellence NICE logo

NICE backs constipation treatment

Sucampo’s Amitiza set for NHS use in England and Wales

UK flag

NICE guidelines on atrial fibrillation discourage aspirin use

Health watchdog encourages greater NHS use of new anticoagulant drugs

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links